Scarica l'app Stockscreener
91.93
0.63%
-0.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
Invest Outside the U.S. With These Top International ETFs - The Motley Fool
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Nasdaq
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Sahm
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus
AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer - Stock Titan
AstraZeneca (LON:AZN) Insider Sells £40,083.12 in Stock - MarketBeat
FDA grants breakthrough therapy designation to AstraZeneca’s ENHERTU for HER2-positive early breast cancer - Investing.com UK
AstraZeneca PLCUpdate on LATIFY Phase III trial of ceralasertib - Research Tree
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
Jacobio Strikes New Cancer Drug Deal with AstraZeneca - marketscreener.com
AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor - marketscreener.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView — Track All Markets
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometr - GuruFocus
AstraZeneca pulls Andexxa from US market after post-marketing fatalities - Pharmaceutical Technology
Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival - marketscreener.com
AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US - marketscreener.com
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles - Vox Markets
AstraZeneca’s lung cancer trial fails to meet primary endpoint - Investing.com
AstraZeneca’s Enhertu gets FDA Breakthrough Therapy status for breast cancer - Investing.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US - marketscreener.com
AstraZeneca’s ceralasertib fails to meet primary endpoint in lung cancer trial - Investing.com Nigeria
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial - Reuters
AstraZeneca's Lung Cancer Drug Misses Phase 3 Survival Goal - marketscreener.com
AstraZeneca says Latify phase III trial fails to meet primary endpoint in NSCLC - marketscreener.com
AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial - marketscreener.com
AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor - Citeline News & Insights
Jacobio Pharma signs $2 billion license deal with AstraZeneca for cancer drug - Investing.com Nigeria
AstraZeneca PLC $AZN Position Boosted by Benson Investment Management Company Inc. - MarketBeat
Published on: 2025-12-20 18:56:48 - ulpravda.ru
AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims - Law360
Why global investors buy Precidian ETFs Trust AstraZeneca PLC stockRisk Management & Consistent Growth Stock Picks - Улправда
AstraZeneca PLC (AZN) Announces Approval of Saphnelo by the European Union - Insider Monkey
AstraZeneca (LON:AZN) Reaches New 1-Year HighHere's What Happened - MarketBeat
AstraZeneca (AZN) Among Companies Prepping Price Reductions - GuruFocus
AstraZeneca to Halt Andexxa Sales in US Over FDA Safety Concerns - marketscreener.com
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns - GuruFocus
AstraZeneca director gifts 5,735 shares to spouse in off-market transaction - Investing.com India
Voya Investment Management LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (AZN) reports director Philip Broadley gifting 5,735 shares - Stock Titan
16,277 Shares in AstraZeneca PLC $AZN Bought by Montecito Bank & Trust - MarketBeat
AstraZeneca Discloses Director’s Gift of Shares to Spouse - TipRanks
Can AstraZeneca PLC Depositary Receipt stock double in next 5 yearsQuarterly Risk Review & Entry Point Strategy Guides - Улправда
Published on: 2025-12-19 13:27:35 - Улправда
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):